Cargando…
Risk interrelationship among multiple primary tumors: A case report and review of literature
RATIONALE: Along with advanced management in oncology, great progress has been recently achieved in the studies of multiple primary tumors. Several reports have studied the coexistence between lymphoma and either renal cell carcinoma (RCC) or Warthin tumor. However, the level of coexistence between...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908637/ https://www.ncbi.nlm.nih.gov/pubmed/29642151 http://dx.doi.org/10.1097/MD.0000000000010289 |
_version_ | 1783315750791938048 |
---|---|
author | Safi, Mohammed Sun, Xiuhua Wang, Lifen Zhang, Xinwei Song, Jicheng Ameen, Mohammed |
author_facet | Safi, Mohammed Sun, Xiuhua Wang, Lifen Zhang, Xinwei Song, Jicheng Ameen, Mohammed |
author_sort | Safi, Mohammed |
collection | PubMed |
description | RATIONALE: Along with advanced management in oncology, great progress has been recently achieved in the studies of multiple primary tumors. Several reports have studied the coexistence between lymphoma and either renal cell carcinoma (RCC) or Warthin tumor. However, the level of coexistence between these cases remains unclear due to the absence of a distinct link between them. PATIENT CONCERNS: We present a unique case of multiple primary tumors (lymphoma, RCC, and Warthin tumor) in an 80-year-old man and a review of the literature on the coexistence of RCC with lymphoma and lymphoma with Warthin tumor. DIAGNOSIS: With a history of RCC, the patient had a freely movable lump under his left ear, and the pathological report indicated Hodgkin lymphoma and Warthin tumor. INTERVENTION: RCC and Warthin tumor of the patient were surgically treated, followed by 2 cycles (14 days per cycle) of Epirubicin 40 mg day 1, Bleomycin 8 mg day 1, Vincristine 2 mg day 1, and Dacarbazine 500 mg day 1. The chemotherapy protocol was then changed to Epirubicin 40 mg day 1, Vincristine 2 mg day 1, and Dacarbazine 500 mg day 1 for 7 cycles. OUTCOMES: After the last day of chemotherapy, the patient showed a complete response. LESSONS: To the best of our knowledge, this paper is the first to report a case of multiple primary tumors with a complete response. For their early detection, favorable prognosis, and correlation identification, we suggest a transitive relation between these coexisting tumors. Therefore, similar studies should be conducted. |
format | Online Article Text |
id | pubmed-5908637 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-59086372018-04-30 Risk interrelationship among multiple primary tumors: A case report and review of literature Safi, Mohammed Sun, Xiuhua Wang, Lifen Zhang, Xinwei Song, Jicheng Ameen, Mohammed Medicine (Baltimore) 4100 RATIONALE: Along with advanced management in oncology, great progress has been recently achieved in the studies of multiple primary tumors. Several reports have studied the coexistence between lymphoma and either renal cell carcinoma (RCC) or Warthin tumor. However, the level of coexistence between these cases remains unclear due to the absence of a distinct link between them. PATIENT CONCERNS: We present a unique case of multiple primary tumors (lymphoma, RCC, and Warthin tumor) in an 80-year-old man and a review of the literature on the coexistence of RCC with lymphoma and lymphoma with Warthin tumor. DIAGNOSIS: With a history of RCC, the patient had a freely movable lump under his left ear, and the pathological report indicated Hodgkin lymphoma and Warthin tumor. INTERVENTION: RCC and Warthin tumor of the patient were surgically treated, followed by 2 cycles (14 days per cycle) of Epirubicin 40 mg day 1, Bleomycin 8 mg day 1, Vincristine 2 mg day 1, and Dacarbazine 500 mg day 1. The chemotherapy protocol was then changed to Epirubicin 40 mg day 1, Vincristine 2 mg day 1, and Dacarbazine 500 mg day 1 for 7 cycles. OUTCOMES: After the last day of chemotherapy, the patient showed a complete response. LESSONS: To the best of our knowledge, this paper is the first to report a case of multiple primary tumors with a complete response. For their early detection, favorable prognosis, and correlation identification, we suggest a transitive relation between these coexisting tumors. Therefore, similar studies should be conducted. Wolters Kluwer Health 2018-04-13 /pmc/articles/PMC5908637/ /pubmed/29642151 http://dx.doi.org/10.1097/MD.0000000000010289 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-nc-sa/4.0 |
spellingShingle | 4100 Safi, Mohammed Sun, Xiuhua Wang, Lifen Zhang, Xinwei Song, Jicheng Ameen, Mohammed Risk interrelationship among multiple primary tumors: A case report and review of literature |
title | Risk interrelationship among multiple primary tumors: A case report and review of literature |
title_full | Risk interrelationship among multiple primary tumors: A case report and review of literature |
title_fullStr | Risk interrelationship among multiple primary tumors: A case report and review of literature |
title_full_unstemmed | Risk interrelationship among multiple primary tumors: A case report and review of literature |
title_short | Risk interrelationship among multiple primary tumors: A case report and review of literature |
title_sort | risk interrelationship among multiple primary tumors: a case report and review of literature |
topic | 4100 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908637/ https://www.ncbi.nlm.nih.gov/pubmed/29642151 http://dx.doi.org/10.1097/MD.0000000000010289 |
work_keys_str_mv | AT safimohammed riskinterrelationshipamongmultipleprimarytumorsacasereportandreviewofliterature AT sunxiuhua riskinterrelationshipamongmultipleprimarytumorsacasereportandreviewofliterature AT wanglifen riskinterrelationshipamongmultipleprimarytumorsacasereportandreviewofliterature AT zhangxinwei riskinterrelationshipamongmultipleprimarytumorsacasereportandreviewofliterature AT songjicheng riskinterrelationshipamongmultipleprimarytumorsacasereportandreviewofliterature AT ameenmohammed riskinterrelationshipamongmultipleprimarytumorsacasereportandreviewofliterature |